C-reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma

Int J Urol. 2019 Nov;26(11):1076-1077. doi: 10.1111/iju.14084. Epub 2019 Jul 31.

Authors

Jun Teishima¹, Daiki Murata², Yasuhisa Hasegawa³, Hiroyuki Moriyama⁴, Koji Mita², Akio Matsubara¹

Affiliations

¹ Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
² Department of Urology, Hiroshima-City Asa Citizens Hospital, Hiroshima, Japan.
³ Department of Urology, Fukuyama Medical Center, Fukuyama, Japan.
⁴ Department of Urology, JA Onomichi General Hospital, Onomichi, Japan.

PMID: 31368187
DOI: 10.1111/iju.14084

No abstract available

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Biomarkers / blood
C-Reactive Protein / metabolism*
Carcinoma, Renal Cell / blood
Carcinoma, Renal Cell / drug therapy*
Humans
Kidney Neoplasms / blood
Kidney Neoplasms / drug therapy*
Nivolumab / therapeutic use*

Substances

Antineoplastic Agents, Immunological
Biomarkers
Nivolumab
C-Reactive Protein